VitaDAO’s Substack
Subscribe
Sign in
Home
Archive
About
Meet Aubrai and His $100K Hypothesis Challenge for Longevity Research
VitaDAO launched Aubrai, our first AI agent.
Sep 12, 2025
•
VitaDAO
4
1
Latest
Top
Discussions
ARTAN Bio (VitaRNA) and Syenex Team Up to Accelerate Next-Generation Anti-Aging Therapy
ARTAN Bio(VitaRNA) and Syenex just announced a strategic collaboration that could significantly speed up the development of ARTAN-102, a pioneering gene…
Jun 26, 2025
•
VitaDAO
DeSci in Action: VitaRNA Tokenized Gene Therapy Achieves Key Safety Milestone in First Animal Studie
VitaRNA has released first in vivo data showing their lead gene therapy candidate, ARTAN-102, is safe and reaches multiple tissues in mice. The 14-day…
Jun 10, 2025
•
VitaDAO
1
1
1
VitaDAO 2024 Highlights
High-Level KPIs*
Jan 29, 2025
•
VitaDAO
4
VitaLabs Projects Up for Voting: Help Pick the Next Big Ideas
About VitaLabs
Jan 27, 2025
•
VitaDAO
4
1
VitaRNA: $1M Fundraise as First Tokenized Gene Therapy Project Advances to Animal Studies
In a significant milestone for decentralized science (DeSci), VitaRNA/Artan Bio has announced a $1M fundraise to support their groundbreaking gene…
Jan 12, 2025
•
VitaDAO
1
November 2024 Longevity Research Newsletter
Introduction
Dec 24, 2024
•
VitaDAO
VITA-FAST Progress Update
During the latest VitaDAO community call, the VitaFast team shared an exciting breakthrough in their autophagy research.
Dec 4, 2024
•
VitaDAO
See all
VitaDAO’s Substack
VitaDAO is a community owned collective funding early stage longevity research,governed by $VITA-holders 🧬 👉https://vitadao.com
Subscribe
Recommendations
Vibe Bio
Vibe Bio
VitaDAO’s Substack
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
